Cuál es el precio por Paion AG (PA8)

Precio por Paion AG (PA8) es de$0.42701586

Cuál es la capitalización de mercado por Paion AG (PA8)

Capitalización de mercado por Paion AG (PA8) es $3.21M

Paion AG (PA8) Historial de Precios

Paion AG is a specialized pharmaceutical firm engaged in the global development and commercialization of medicines for hospital settings, specifically addressing needs in sedation, anesthesia, and critical care. Its primary compound, Remimazolam, is an ultra-short-acting intravenous benzodiazepine designed as a sedative/anesthetic, currently progressing through clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor for treating severe low blood pressure in adults experiencing septic or other forms of distributive shock, and Eravacycline, a new fluorocycline antibiotic targeting complex intra-abdominal infections in adults. Paion AG collaborates with various partners through licensing and strategic agreements, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Established in 2000, Paion AG operates from Aachen, Germany.

Año	Rendimiento
2023	-93.62%
2022	0.00%

Año

Rendimiento

2023

-93.62%

2022

0.00%

Empresa	Precio de la acción	Cambio 1a%	País
MERCK Kommanditgesellschaft auf Aktien MER.SW	$171.67	-	DE
Merck KGaA MRK.DE	$161.67	23.26%	DE
Takeda Pharmaceutical Company Limited 4502.T	$36.61	22.16%	JP
Galderma Group AG GALD.SW	$225.00	37.51%	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	$21.30	13.79%	IN

Empresa

Precio de la acción

Cambio 1a%

País